source
- FDA says trial manipulation undermines approval of ChemoCentryx's Tavneos, now owned by AmgenThe U.S. Food and Drug Administration has announced that it believes the pivotal trial supporting the approval of Tavneos was manipulated. The agency says ChemoCentryx, which was acquired by Amgen…
- Incyte reports positive Phase 3 results for povorcitinib in nonsegmental vitiligo, plans FDA filingIncyte announced that its oral JAK1 inhibitor povorcitinib achieved positive outcomes in two Phase 3 trials targeting nonsegmental vitiligo. The studies met their primary endpoints, demonstrating…